Skip to main content

Table 1 Patient demographics and disease characteristics at baseline

From: Nivolumab plus ipilimumab versus nivolumab in individuals with treatment-naive programmed death-ligand 1 positive metastatic soft tissue sarcomas: a multicentre retrospective study

Variable

NPI (n=74)

NIV (n=76)

p-value

Age, years

 Median (range)

35 (21.2–51.8)

34 (23.8–57.3)

0.105

Sex, n (%)

  

0.729

 Male

42 (56.8)

41 (53.9)

 

 Female

32 (43.2)

35 (46.1)

 

BMI, kg/m2

 Median (range)

25.7 (17.1–41.3)

25.4 (15.6–43.7)

0.256

ECOG performance status, n (%)

  

0.619

 0

40 (54.1)

38 (50.0)

 

 1

34 (45.9)

38 (50.0)

 

Sarcoma typesa, n (%)

  

0.764

 Non-uterine leiomyosarcoma

43 (58.1)

40 (52.6)

 

 Liposarcomab

20 (27.0)

22 (28.9)

 

 Synovial sarcoma

11 (14.9)

14 (18.4)

 

Three major types of liposarcoma

  

0.078

 Atypical lipoma

9 (12.1)

11 (14.5)

 

 Myxoid liposarcoma

10 (13.5)

9 (11.8)

 

 Pleomorphic liposarcoma

1 (1.4)

2 (2.6)

 

Histological grade, n (%)

  

0.504

 G1 (well differentiated)

31 (41.9)

37 (48.7)

 

 G2 (moderately differentiated)

27 (36.5)

21 (27.6)

 

 G3 (poorly differentiated)

16 (21.6)

18 (23.7)

 

TMBc status (per Mb), n (%)

  

0.716

 TMB-High (> 5)

45 (60.8)

44 (57.9)

 

 TMB-Low (0–5)

29 (39.2)

32 (42.1)

 

Duration of treatment (months)

   

 Median (range)

3 (1.5–4.4)

3 (1.6–4.7)

0.317

Number of metastatic sites, n (%)

  

0.583

 3

12 (16.2)

10 (13.2)

 

 > 3

51 (68.9)

58 (76.3)

 

 Unknown

11(14.9)

8 (10.5)

 
  1. aBased on a central review of pathology; bPrimary liposarcomas were located in the lower extremity (11%), upper extremity (6%), the trunk wall (11%), the retroperitoneum (64%), and the head and neck (8%); cdefined as the number of somatic coding base substitution and indels per megabase of genome. NPI nivolumab plus ipilimumab, NIV nivolumab, BMI body mass index, ECOG Eastern Collaborative Oncology Group, TMB tumour mutation burden